These detailed findings highlight the selective regulatory effects of BKS-112 on HDAC expression, providing valuable insights into its potential therapeutic role in targeting HDACs specifically associated with triple-negative breast cancer (TNBC). The gene discussed is HDAC9; the disease is triple-negative breast carcinoma.